AJANTPHARM · NSE
Ajanta Pharma Limited
₹3,317.7
+1.45% (+₹47.4)
Prev. close
₹3,270.3
Volume
84,184
Delivery %
57.7%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Prabhudas Lilladher recommends buying Ajanta Pharma with a target price of ₹3,200. The call implies a bullish outlook on…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Ajanta Pharma Ltd | HIT | |
| “Maintains a 'BUY' rating on Ajanta Pharma with a target of ₹3,200, valuing it at 30x PE on September 2027 earnings. The …” | PL Capital AnalysisPL Capital | Ajanta Pharma | HIT | |
| “Bullish on Ajanta Pharma for the next 1-2 weeks, recommending a buy at ₹2,610.70 with a target of ₹2,880 and a stop loss…” | Hitesh TailorChoice Equity Broking | Ajanta Pharma | MISS | |
| “Bullish on Ajanta Pharma, identifying it as a relative outperformer in the current market environment where pharma stock…” | Aditya AroraAdlytick | Ajanta Pharma Limited | MISS | |
| “Bullish on Ajanta Pharma Ltd, which is in a strong uptrend across all time frames, forming higher tops and bottoms and t…” | Rajesh PalviyaAxis Securities | Ajanta Pharma Ltd | PENDING |
Market commentary · 5 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Motilal Oswal expects strong gains for Ajanta Pharma, projecting up to 17% upside, driven by its new weight loss drug. T…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Ajanta Pharma Ltd | — | |
| “Recommends Ajanta Pharma, offering an 18.9% upside, backed by favorable technical trends. This is a mid-cap conviction p…” | InCred Equities AnalysisInCred Equities | Ajanta Pharma Ltd | — | |
| “Ajanta Pharma is a stock that could move from the mid-cap to small-cap category in AMFI's January 2026 review, effective…” | Abhilash PagariaNuvama | Ajanta Pharma Ltd | — | |
| “Recommends an 'Add' rating on Ajanta Pharma for June 2025, supported by a favorable monsoon forecast and robust GVA grow…” | InCred Equities AnalysisInCred Equities | Ajanta Pharma Ltd | — | |
| “Initiated coverage on Ajanta Pharma with a 'buy' rating, projecting an 11% upside from current levels. This positive out…” | Jefferies AnalysisJefferies | Ajanta Pharma Ltd | — |
Fundamentals
About Ajanta Pharma Limited
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Yogesh Mannalal Agrawal M.B.A
Headquarters
Mumbai
Employees
10,421
Website
ajantapharma.comExchange
View on NSE ↗Key stats
Market cap
₹41,445.16 Cr
P/E ratio (TTM)
32.8
Dividend yield
1.93%
EPS (TTM)
₹101.01
Beta (1Y · daily vs NIFTY 50)
0.47
Beta (5Y · monthly vs NIFTY 50)
0.72
Shares float
4.20 Cr
EPS · quarter ended Sept 2026
₹31.03
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
Total assets for FY23, FY24, FY25 and FY26: the figure the company printed, which its own totals confirm and the series' figure did not.
08 · Profit & Loss — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,915.67 Cr | ₹3,456.67 Cr | ₹3,841.28 Cr | ₹4,293.31 Cr | ₹4,742.60 Cr | ₹5,624.93 Cr | |
| ₹2,015.49 Cr | ₹2,547.19 Cr | ₹3,096.03 Cr | ₹3,179.38 Cr | ₹3,553.44 Cr | ₹4,247.28 Cr | |
Profit before tax | ₹900.18 Cr | ₹909.48 Cr | ₹745.25 Cr | ₹1,113.93 Cr | ₹1,189.16 Cr | ₹1,377.65 Cr |
| ₹246.31 Cr | ₹196.79 Cr | ₹157.27 Cr | ₹297.76 Cr | ₹268.77 Cr | ₹321.65 Cr | |
| ₹647.42 Cr | ₹704.71 Cr | ₹602.83 Cr | ₹816.98 Cr | ₹922.24 Cr | ₹1,085.08 Cr | |
Profit for the year | ₹653.87 Cr | ₹712.68 Cr | ₹587.98 Cr | ₹816.17 Cr | ₹920.39 Cr | ₹1,056.00 Cr |
| ₹-6.45 Cr | ₹-7.97 Cr | ₹14.85 Cr | ₹81.00 L | ₹1.85 Cr | ₹29.08 Cr | |
Basic (*) | 75.09 | 54.97 | 45.89 | 64.82 | 73.56 | 84.53 |
Diluted (₹) | 75.09 | 54.96 | 45.89 | 64.77 | 73.53 | 84.51 |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
09 · Balance Sheet — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,751.13 Cr | ₹1,791.12 Cr | ₹1,845.02 Cr | ₹1,907.47 Cr | ₹2,171.92 Cr | ₹2,419.41 Cr | |
(a) Inventories | ₹766.47 Cr | ₹791.07 Cr | ₹815.63 Cr | ₹828.36 Cr | ₹903.85 Cr | ₹938.54 Cr |
(i) Investments | ₹175.67 Cr | ₹121.86 Cr | ₹510.27 Cr | ₹330.05 Cr | ₹438.71 Cr | ₹559.85 Cr |
(ii) Trade receivables | ₹738.43 Cr | ₹1,019.81 Cr | ₹1,056.90 Cr | ₹1,246.84 Cr | ₹1,182.74 Cr | ₹1,853.88 Cr |
(iii) Cash and cash equivalents | ₹177.51 Cr | ₹206.36 Cr | ₹329.83 Cr | ₹129.49 Cr | ₹175.12 Cr | ₹103.26 Cr |
(iv) Bank balances other than cash and cash equivalents | ₹32.10 Cr | ₹5.43 Cr | ₹1.07 Cr | ₹1.28 Cr | ₹1.12 Cr | ₹1.51 Cr |
(v) Loans | ₹8.03 Cr | ₹6.37 Cr | ₹17.39 Cr | ₹33.96 Cr | ₹2.54 Cr | ₹1.68 Cr |
Other financial assets | ₹5.86 Cr | ₹17.69 Cr | — | — | — | — |
(vi) Other financial assets | ₹16.37 Cr | ₹12.04 Cr | ₹2.48 Cr | ₹19.02 Cr | ₹2.32 Cr | ₹8.98 Cr |
(c) Other current assets | ₹123.52 Cr | ₹95.87 Cr | ₹91.61 Cr | ₹133.07 Cr | ₹123.30 Cr | ₹267.73 Cr |
| — | — | ₹2,834.00 Cr | — | ₹2,843.03 Cr | ₹3,735.43 Cr | |
Total current assets | ₹2,027.59 Cr | ₹2,264.46 Cr | ₹2,825.18 Cr | ₹2,730.92 Cr | ₹2,829.70 Cr | ₹3,735.43 Cr |
(d) Assets classified as held for sale | — | — | ₹8.82 Cr | ₹8.85 Cr | ₹13.33 Cr | — |
Total assets | ₹3,778.72 Cr | ₹4,055.58 Cr | ₹4,679.02 Cr | ₹4,638.39 Cr | ₹5,014.95 Cr | ₹6,154.84 Cr |
| ₹2,995.63 Cr | ₹3,264.34 Cr | ₹3,387.99 Cr | ₹3,567.36 Cr | ₹3,790.29 Cr | ₹4,527.09 Cr | |
Other Liabilities | ₹3.34 Cr | ₹3.00 Cr | — | — | — | — |
(i) Lease liabilities | ₹18.17 Cr | ₹16.93 Cr | ₹24.95 Cr | ₹23.52 Cr | ₹34.72 Cr | ₹39.42 Cr |
(ii) Other financial liabilities | ₹1.25 Cr | ₹1.09 Cr | ₹1.01 Cr | ₹1.37 Cr | ₹1.05 Cr | ₹1.82 Cr |
(b) Other non current liabilities | — | — | ₹2.67 Cr | ₹2.34 Cr | ₹2.00 Cr | ₹1.67 Cr |
(c) Provisions | ₹17.93 Cr | ₹19.32 Cr | ₹24.15 Cr | ₹39.54 Cr | ₹80.27 Cr | ₹51.15 Cr |
(d) Deferred tax liabilities (net) | ₹92.17 Cr | ₹101.87 Cr | ₹97.72 Cr | ₹108.50 Cr | ₹110.52 Cr | ₹117.94 Cr |
Total non-current liabilities | ₹134.46 Cr | ₹143.85 Cr | ₹151.75 Cr | ₹175.27 Cr | ₹228.56 Cr | ₹212.00 Cr |
Borrowings | ₹9.00 L | ₹27.00 L | ₹18.00 L | — | — | — |
(i) Borrowings | ₹1.60 Cr | ₹1.64 Cr | ₹1.25 Cr | ₹1.49 Cr | ₹2.59 Cr | ₹211.99 Cr |
(ii) Lease liabilities | ₹11.50 Cr | ₹6.19 Cr | ₹9.25 Cr | ₹10.27 Cr | ₹10.11 Cr | ₹8.76 Cr |
Other liabilities | ₹30.42 Cr | ₹64.42 Cr | — | — | — | — |
(a) total outstanding dues of micro and small enterprises; and | ₹24.48 Cr | ₹27.98 Cr | ₹37.94 Cr | ₹20.64 Cr | ₹21.55 Cr | ₹54.17 Cr |
(b) total outstanding dues of creditors other than micro and small enterprises. | ₹349.38 Cr | ₹299.19 Cr | ₹384.83 Cr | ₹442.56 Cr | ₹432.65 Cr | ₹490.13 Cr |
(iv) Other financial liabilities | ₹172.13 Cr | ₹230.59 Cr | ₹636.84 Cr | ₹298.03 Cr | ₹374.20 Cr | ₹495.82 Cr |
(b) Other current liabilities | — | — | ₹23.15 Cr | ₹59.73 Cr | ₹91.12 Cr | ₹119.00 Cr |
(c) Provisions | ₹11.71 Cr | ₹10.81 Cr | ₹14.02 Cr | ₹17.76 Cr | ₹23.35 Cr | ₹30.39 Cr |
(d) Income tax liabilities (net) | ₹48.92 Cr | ₹7.94 Cr | ₹33.07 Cr | ₹44.77 Cr | ₹40.53 Cr | ₹5.49 Cr |
| — | — | ₹1,139.28 Cr | — | — | — | |
Total current liabilities | ₹648.63 Cr | ₹647.39 Cr | ₹1,139.28 Cr | ₹895.76 Cr | ₹996.10 Cr | ₹1,415.75 Cr |
Total liabilities | ₹783.09 Cr† | ₹791.24 Cr | ₹1,291.03 Cr | ₹1,071.03 Cr | ₹1,224.66 Cr | ₹1,627.74 Cr |
Total Equity and Liabilities | ₹3,778.72 Cr | ₹4,055.58 Cr | ₹4,679.02 Cr | ₹4,638.39 Cr | ₹5,014.95 Cr | ₹6,154.84 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
† Computed, not printed: that year’s report leaves this figure out, but the lines it does print fix it exactly (hover for the sum). The same relationship holds in every year where all of its lines are printed.
All years: consolidated statements.
10 · Cash Flow Statement — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹576.31 Cr | ₹561.71 Cr | ₹792.11 Cr | ₹785.07 Cr | ₹1,157.23 Cr | ₹529.19 Cr | |
| ₹-282.38 Cr | ₹-74.10 Cr | ₹-559.60 Cr | ₹65.39 Cr | ₹-376.52 Cr | ₹-428.92 Cr | |
| ₹-24.36 Cr | ₹27.90 Cr | ₹124.31 Cr | ₹-200.60 Cr | ₹47.30 Cr | ₹-67.65 Cr | |
Cash and cash equivalents as at the beginning of the year | ₹202.35 Cr | ₹177.51 Cr | ₹206.36 Cr | ₹329.83 Cr | ₹129.49 Cr | ₹175.12 Cr |
Cash and cash equivalents as at the end of the year | ₹177.99 Cr | ₹205.41 Cr | ₹330.67 Cr | ₹129.23 Cr | ₹176.79 Cr | ₹107.47 Cr |
| ₹177.51 Cr | ₹206.36 Cr | ₹329.83 Cr | ₹129.49 Cr | ₹175.12 Cr | ₹103.26 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Dec 21(2Q) | Mar 22–Sep 22(3Q) | Dec 22–Mar 23(2Q) | Apr 23–Mar 24(5Q) | Jun 24 | Sep 24–Jun 25(4Q) | Sep 25–Mar 26(3Q) | Jun 26 |
|---|---|---|---|---|---|---|---|---|
| Promoter | 70.34% | 70.48% | 66.11% | 66.21% | 66.27% | 66.26% | 66.25% | 63.48% |
| Public | 29.66% | 29.52% | 33.89% | 33.79% | 33.73% | 33.74% | 33.75% | 36.52% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Ajanta Pharma Limited | ₹41,482.65 Cr | ₹3,316.7 | 32.9 | 9.16 | 23.3% | 0.06 | +17.9% | +27.0% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Ajanta Pharma Q2 FY27 Earnings Call Transcript Now Available
Ajanta Pharma Limited has made the transcript of its Q2 FY27 earnings call publicly available on its investor relations website. The call, held on October 30, 2026, discussed the company's financial performance for the July to September 2026 quarter. This disclosure fulfills regulatory obligations and provides investors access to management commentary.
Pharma sector stocks today, November 3: J.B. Chemicals falls 3.87%, Biocon down 2.76%, Ajanta Pharma declines 1.58%
Business Upturn · 19 days ago